MCID: LTR001
MIFTS: 58

Lateral Sclerosis

Categories: Rare diseases, Neuronal diseases, Genetic diseases

Aliases & Classifications for Lateral Sclerosis

MalaCards integrated aliases for Lateral Sclerosis:

Name: Lateral Sclerosis 12 15 73
Primary Lateral Sclerosis 12 76 53 54 55
Adult-Onset Primary Lateral Sclerosis 12 53
Motor Neuron Disease 44 73
Adult-Onset Pls 53

Classifications:



External Ids:

Disease Ontology 12 DOID:230
ICD10 33 G12.29
ICD9CM 35 335.24
MeSH 44 D016472
SNOMED-CT 68 81211007
UMLS 73 C0154682

Summaries for Lateral Sclerosis

NINDS : 54 Primary lateral sclerosis (PLS) is a rare neuromuscular disease with slowly progressive weakness in voluntary muscle movement. PLS belongs to a group of disorders known as motor neuron diseases. PLS affects the upper motor neurons (also called corticospinal neurons) in the arms, legs, and face.  It occurs when nerve cells in the motor regions of the cerebral cortex (the thin layer of cells covering the brain which is responsible for most higher level mental functions) gradually degenerate, causing movements to be slow and effortful.  The disorder often affects the legs first, followed by the body, trunk, arms and hands, and, finally the bulbar muscles (muscles that control speech, swallowing, and chewing).  Symptoms include weakness, muscle stiffness and spasticity, clumsiness, slowing of movement, and problems with balance and speech. PLS is more common in men than in women, with a varied gradual onset that generally occurs between ages 40 and 60. PLS progresses gradually over a number of years, or even decades. Scientists do not believe PLS has a simple hereditary cause.  The diagnosis of PLS requires extensive testing to exclude other diseases. When symptoms begin, PLS may be mistaken for amyotrophic lateral sclerosis (ALS) or spastic paraplegia.  Most neurologists follow an affected individual's clinical course for at least 3 to 4 years before making a diagnosis of PLS.

MalaCards based summary : Lateral Sclerosis, also known as primary lateral sclerosis, is related to amyotrophic lateral sclerosis 2, juvenile and amyotrophic lateral sclerosis type 6, and has symptoms including ataxia, muscular fasciculation and hemiplegia. An important gene associated with Lateral Sclerosis is ALS2 (ALS2, Alsin Rho Guanine Nucleotide Exchange Factor), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Riluzole and Mexiletine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs.

NIH Rare Diseases : 53 Primary lateral sclerosis (PLS) is a rare neuromuscular disease that affects the nerve cells that control the voluntary muscles. Problems in the legs (such as weakness, stiffness, spasticity, and balance problems) are often observed first, but hand clumsiness and changes in speech can be early symptoms, as well. The condition is progressive (gradually becomes worse over time); however, affected people have a normal life expectancy. The underlying cause of adult PLS is currently unknown. In most cases, it occurs sporadically in people with no family history of the condition. A subtype of PLS, called juvenile PLS, is caused by changes (mutations) in the ALS2 gene and is inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

Wikipedia : 76 Primary lateral sclerosis (PLS) is a rare neuromuscular disease characterized by progressive muscle... more...

Related Diseases for Lateral Sclerosis

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile Primary Lateral Sclerosis, Adult, 1

Diseases related to Lateral Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
# Related Disease Score Top Affiliating Genes
1 amyotrophic lateral sclerosis 2, juvenile 34.9 ALS2 ALS2CR12 SOD1
2 amyotrophic lateral sclerosis type 6 34.8 ALS2 FUS SETX TARDBP
3 amyotrophic lateral sclerosis 16, juvenile 34.8 ALS2 SIGMAR1 SOD1
4 amyotrophic lateral sclerosis 4, juvenile 34.7 ALS2 SETX
5 amyotrophic lateral sclerosis 18 34.7 C9orf72 FUS SOD1 TARDBP
6 juvenile amyotrophic lateral sclerosis 34.5 ALS2 FUS SETX SIGMAR1
7 amyotrophic lateral sclerosis 10 with or without frontotemporal dementia 34.2 ALS2 ANG FIG4 FUS SETX TARDBP
8 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 34.2 C9orf72 CHCHD10 FUS TARDBP UBQLN2 VCP
9 amyotrophic lateral sclerosis 11 34.2 ALS2 ANG FIG4 FUS SETX TARDBP
10 amyotrophic lateral sclerosis 9 34.2 ALS2 ANG FIG4 FUS SETX TARDBP
11 amyotrophic lateral sclerosis type 14 34.1 FUS TARDBP UBQLN2 VAPB VCP
12 amyotrophic lateral sclerosis 7 34.1 ALS2 ANG FIG4 FUS SETX TARDBP
13 amyotrophic lateral sclerosis 21 34.0 C9orf72 FUS SETX SOD1 TARDBP VAPB
14 progressive muscular atrophy 32.3 C9orf72 TARDBP
15 perry syndrome 32.3 C9orf72 DCTN1 TARDBP
16 frontotemporal dementia 32.3 C9orf72 CHCHD10 FUS HNRNPA1 NEFH SOD1
17 nervous system disease 32.2 C9orf72 FUS SOD1 TARDBP
18 motor neuron disease 31.1 ALS2 C9orf72 CHCHD10 DCTN1 FUS NEFH
19 progressive non-fluent aphasia 30.6 C9orf72 VCP
20 spinal muscular atrophy 30.6 CHCHD10 HNRNPA1 SIGMAR1 VAPB
21 semantic dementia 30.2 C9orf72 TARDBP
22 charcot-marie-tooth disease 30.1 DCTN1 FIG4 NEFH SETX VCP
23 dementia 30.0 C9orf72 CHCHD10 FUS HNRNPA1 TARDBP TRPM7
24 amyotrophic lateral sclerosis 1 29.3 ALS2 ANG C9orf72 CHCHD10 DCTN1 FIG4
25 primary lateral sclerosis, juvenile 12.6
26 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 12.5
27 amyotrophic lateral sclerosis 8 12.5
28 amyotrophic lateral sclerosis 19 12.5
29 primary lateral sclerosis, adult, 1 12.4
30 amyotrophic lateral sclerosis 6 with or without frontotemporal dementia 12.4
31 amyotrophic lateral sclerosis 17 12.4
32 amyotrophic lateral sclerosis 12 12.4
33 amyotrophic lateral sclerosis 14 with or without frontotemporal dementia 12.4
34 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 12.4
35 amyotrophic lateral sclerosis 20 12.4
36 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 12.4
37 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 12.4
38 amyotrophic lateral sclerosis 15 with or without frontotemporal dementia 12.3
39 amyotrophic lateral sclerosis 3 12.3
40 amyotrophic lateral sclerosis type 5 12.3
41 amyotrophic lateral sclerosis 23 12.3
42 amyotrophic lateral sclerosis 22 with or without frontotemporal dementia 12.3
43 amyotrophic lateral sclerosis 5, juvenile 12.3
44 amyotrophic lateral sclerosis type 15 12.3
45 amyotrophic lateral sclerosis, juvenile, with dementia 12.3
46 amyotrophic lateral sclerosis type 22 12.2
47 c9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia 12.1
48 tardbp-related amyotrophic lateral sclerosis 12.1
49 amyotrophic lateral sclerosis 24 12.1
50 amyotrophic lateral sclerosis 25 12.1

Graphical network of the top 20 diseases related to Lateral Sclerosis:



Diseases related to Lateral Sclerosis

Symptoms & Phenotypes for Lateral Sclerosis

UMLS symptoms related to Lateral Sclerosis:


ataxia, muscular fasciculation, hemiplegia, myoclonus

GenomeRNAi Phenotypes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.39 DCTN1
2 Decreased viability GR00221-A-1 10.39 TRPM7
3 Decreased viability GR00221-A-2 10.39 SOD1 TRPM7
4 Decreased viability GR00221-A-3 10.39 SOD1
5 Decreased viability GR00221-A-4 10.39 FUS SOD1 TRPM7
6 Decreased viability GR00342-S-2 10.39 TRPM7
7 Decreased viability GR00381-A-1 10.39 ANG FIG4 SIGMAR1 VCP
8 Decreased viability GR00381-A-3 10.39 SIGMAR1
9 Decreased viability GR00402-S-2 10.39 ALS2 ALS2CR12 ANG C9orf72 CHCHD10 DCTN1
10 no effect GR00402-S-1 9.96 UBQLN2 VAPB VCP ALS2 ALS2CR12 ANG
11 shRNA abundance <= 50% GR00343-S 9.32 ANG FUS HNRNPA1 RNF19A SETX SOD1

MGI Mouse Phenotypes related to Lateral Sclerosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 ALS2 C9orf72 DCTN1 FIG4 NEFH SIGMAR1
2 cellular MP:0005384 9.65 C9orf72 CHCHD10 DCTN1 NEFH SETX SOD1
3 nervous system MP:0003631 9.36 TARDBP TRPM7 VAPB VCP ALS2 C9orf72

Drugs & Therapeutics for Lateral Sclerosis

Drugs for Lateral Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1744-22-5 5070
2
Mexiletine Approved, Investigational Phase 4,Phase 2 31828-71-4 4178
3
Armodafinil Approved, Investigational Phase 4 112111-43-0
4
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
5 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
10 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
12 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Phase 1
13 Sodium Channel Blockers Phase 4,Phase 3,Phase 2,Phase 1
14 Central Nervous System Stimulants Phase 4,Phase 1
15 Cytochrome P-450 CYP3A Inducers Phase 4
16 Wakefulness-Promoting Agents Phase 4
17
Olanzapine Approved, Investigational Phase 2, Phase 3 132539-06-1 4585
18
Iron Approved Phase 2, Phase 3,Not Applicable 7439-89-6 23925
19
Antipyrine Approved, Investigational Phase 3,Phase 1,Phase 2 60-80-0 2206
20
Dopamine Approved Phase 2, Phase 3,Phase 3,Phase 1 51-61-6, 62-31-7 681
21
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
22
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 44475014
23
Zinc Approved, Investigational Phase 3,Phase 1,Phase 2 7440-66-6 23994
24
Lenograstim Approved, Investigational Phase 2, Phase 3,Not Applicable 135968-09-1
25
Pramipexole Approved, Investigational Phase 3,Phase 1,Phase 2 104632-26-0 59868 119570
26
Minocycline Approved, Investigational Phase 3,Phase 2 10118-90-8 5281021
27
Valproic Acid Approved, Investigational Phase 3,Phase 2 99-66-1 3121
28
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
29
Acetylcholine Approved Phase 2, Phase 3,Phase 3,Not Applicable 51-84-3 187
30
Dextromethorphan Approved Phase 3,Phase 2 125-71-3 5360696 5362449
31
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2 93-14-1 3516
32
Quinidine Approved, Investigational Phase 3,Phase 2 56-54-2 441074
33
Citalopram Approved Phase 3 59729-33-8 2771
34
Deferiprone Approved Phase 2, Phase 3,Not Applicable 30652-11-0 2972
35
Creatine Approved, Investigational, Nutraceutical Phase 3,Phase 2 57-00-1 586
36
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 13422-55-4
37
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
39
Tocopherol Approved, Investigational, Nutraceutical Phase 3 1406-66-2 14986
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
41
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3,Phase 2 303-98-0 5281915
42 Antiemetics Phase 2, Phase 3
43 Antipsychotic Agents Phase 2, Phase 3,Phase 3
44 Autonomic Agents Phase 2, Phase 3,Phase 3,Phase 1
45 Central Nervous System Depressants Phase 2, Phase 3,Phase 3,Phase 1
46 Gastrointestinal Agents Phase 2, Phase 3,Phase 1
47 Neurotransmitter Uptake Inhibitors Phase 2, Phase 3,Phase 3,Early Phase 1
48 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable
49 Psychotropic Drugs Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Serotonin Agents Phase 2, Phase 3,Phase 3,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 471)
# Name Status NCT ID Phase Drugs
1 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
2 CARE Canadian ALS Riluzole Evaluation Completed NCT00542412 Phase 4 Riluzole
3 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
4 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
5 Modafinil for Treatment of Fatigue in ALS Patients Completed NCT00614926 Phase 4 Modafinil;Placebo
6 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
7 Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3 Olanzapine
8 Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3 Creatine Monohydrate
9 The Objective is to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Completed NCT02588677 Phase 2, Phase 3 Masitinib (AB1010);Riluzole;Placebo
10 Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis Completed NCT01492686 Phase 3 MCI-186;Placebo;MCI-186 in open label phase
11 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00445172 Phase 2, Phase 3 E0302 (mecobalamin)
12 Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) Completed NCT00353665 Phase 2, Phase 3 Memantine (Ebixa);riluzole;Placebo
13 A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3 E0302 (mecobalamin);E0302 (mecobalamin);Placebo
14 Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis Completed NCT00706147 Phase 2, Phase 3 Arimoclomol;Placebo
15 Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00424463 Phase 3 MCI-186;Placebo of MCI-186
16 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial Completed NCT00035815 Phase 3 Insulin like growth factor, type 1;Placebo
17 The Effect of GCSF in the Treatment of ALS Patients Completed NCT01825551 Phase 2, Phase 3 Granulocyte Colony Stimulating Factor;Placebo
18 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Completed NCT00330681 Phase 3 MCI-186;Placebo of MCI-186
19 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III Completed NCT00415519 Phase 3 MCI-186;Placebo of MCI-186
20 Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Completed NCT00868166 Phase 2, Phase 3 Olesoxime;Placebo Comparator
21 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT01933321 Phase 2, Phase 3
22 Phase 3 Study of Dexpramipexole in ALS Completed NCT01281189 Phase 3 Dexpramipexole;Placebo
23 Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis Completed NCT00833820 Phase 2, Phase 3
24 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls Completed NCT01160263 Phase 3 SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
25 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3 minocycline
26 Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS Completed NCT00372879 Phase 3
27 Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis Completed NCT00136110 Phase 3 Sodium Valproate
28 Clinical Trial Ceftriaxone in Subjects With ALS Completed NCT00349622 Phase 3 ceftriaxone
29 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00125203 Phase 2, Phase 3 Botulinum toxin type B (Myobloc)
30 Safety Extension Study of TRO19622 in ALS Completed NCT01285583 Phase 2, Phase 3 TRO19622
31 Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Completed NCT02496767 Phase 3 tirasemtiv;Placebo tablets
32 Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS Completed NCT00021697 Phase 3 AVP-923
33 Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
34 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement Completed NCT00386464 Phase 2, Phase 3
35 Escitalopram (Lexapro) for Depression MS or ALS Completed NCT00965497 Phase 3 escitalopram
36 Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Completed NCT01776970 Phase 2, Phase 3 Cannabis Sativa extract Oromucosal spray
37 Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3 MYOBLOC
38 Clinical Trial of Ultra-high Dose Methylcobalamin for ALS Recruiting NCT03548311 Phase 3 methylcobalamin;saline solution
39 Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients Recruiting NCT03280056 Phase 3
40 Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS Recruiting NCT03505021 Phase 3 Levosimendan;Placebo for levosimendan
41 A Study for Patients Who Completed VITALITY-ALS (CY 4031) Active, not recruiting NCT02936635 Phase 3 tirasemtiv
42 Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) Active, not recruiting NCT01257828 Phase 3 riluzole;Placebo medication
43 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Not yet recruiting NCT03293069 Phase 2, Phase 3 Deferiprone;Placebo Oral Tablet
44 Arimoclomol in Amyotropic Lateral Sclerosis Not yet recruiting NCT03491462 Phase 3 Arimoclomol;Placebo oral capsule
45 Phase 3 Study to Compare the Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients Not yet recruiting NCT03127267 Phase 3 Masitinib Mesylate;Riluzole 50Mg Tablet;Placebo Oral Tablet
46 Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) Not yet recruiting NCT03347344 Phase 3 Riluzole;Placebo
47 Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Terminated NCT00818389 Phase 2, Phase 3 Lithium Carbonate;Riluzole;placebo
48 Phase 3 Extension Study of Dexpramipexole in ALS Terminated NCT01622088 Phase 3 Dexpramipexole
49 Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation Terminated NCT01583088 Phase 3
50 Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS) Terminated NCT01016522 Phase 3

Search NIH Clinical Center for Lateral Sclerosis

Cochrane evidence based reviews: motor neuron disease

Genetic Tests for Lateral Sclerosis

Anatomical Context for Lateral Sclerosis

MalaCards organs/tissues related to Lateral Sclerosis:

41
Brain, Spinal Cord, Testes, Bone, Cortex, Bone Marrow, Skin

Publications for Lateral Sclerosis

Articles related to Lateral Sclerosis:

(show top 50) (show all 2553)
# Title Authors Year
1
Coexistence of Amyotrophic Lateral Sclerosis in the Proband of an X-Linked Charcot-Marie-Tooth Disease Type 1 Pedigree in China. ( 29629536 )
2018
2
Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. ( 29427042 )
2018
3
Imaging of glia activation in people with primary lateral sclerosis. ( 29159046 )
2018
4
Successful Management of Acquired Tracheomalacia of Patients With Amyotrophic Lateral Sclerosis: A Report of Three Cases. ( 29765893 )
2018
5
Whole blood transcriptome analysis in amyotrophic lateral sclerosis: A biomarker study. ( 29939990 )
2018
6
Therapeutic effects of percutaneous endoscopic gastrostomy on survival in patients with amyotrophic lateral sclerosis: A meta-analysis. ( 29408898 )
2018
7
EFFECT OF WEDELOLACTONE AND GALLIC ACID ON QUINOLINIC ACID-INDUCED NEUROTOXICITY AND IMPAIRED MOTOR FUNCTION: SIGNIFICANCE TO SPORADIC AMYOTROPHIC LATERAL SCLEROSIS. ( 29981346 )
2018
8
Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis. ( 29950436 )
2018
9
Impact of expiratory strength training in amyotrophic lateral sclerosis: Results of a randomized sham controlled trial. ( 29981250 )
2018
10
Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. ( 29254092 )
2018
11
A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy. ( 29416499 )
2018
12
Elevated Global DNA Methylation Is Not Exclusive to Amyotrophic Lateral Sclerosis and Is Also Observed in Spinocerebellar Ataxia Types 1 and 2. ( 29428949 )
2018
13
Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. ( 29941342 )
2018
14
Crush injury to motor nerves in the G93A transgenic mouse model of amyotrophic lateral sclerosis promotes muscle reinnervation and survival of functionally intact nerve-muscle contacts. ( 29409912 )
2018
15
Swallowing impairments in Amyotrophic Lateral Sclerosis and Myotonic Dystrophy type 1: Looking for the portrait of dysphagic patient in neuromuscular diseases. ( 29400682 )
2018
16
Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. ( 29942091 )
2018
17
A blended psychosocial support program for partners of patients with amyotrophic lateral sclerosis and progressive muscular atrophy: protocol of a randomized controlled trial. ( 29716660 )
2018
18
Molecular mechanisms underlying the impact of mutations in SOD1 on its conformational properties associated with amyotrophic lateral sclerosis as revealed with molecular modelling. ( 29431095 )
2018
19
Amyotrophic Lateral Sclerosis after Receiving the Human Papilloma Virus Vaccine: A Case Report of a 15-year-old Girl. ( 29434138 )
2018
20
Pseudobulbar Affect Correlates With Mood Symptoms in Parkinsonian Disorders but Not Amyotrophic Lateral Sclerosis. ( 29505320 )
2018
21
Radial diffusivity as an imaging biomarker for early diagnosis of non-demented amyotrophic lateral sclerosis. ( 29948064 )
2018
22
Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. ( 29128630 )
2018
23
No Benefit of Diaphragm Pacing in Upper Motor Neuron Dominant Forms of Amyotrophic Lateral Sclerosis. ( 29957023 )
2018
24
Thoracoabdominal asynchrony and paradoxical motion in middle stage amyotrophic lateral sclerosis. ( 29969705 )
2018
25
Association between TBK1 mutations and risk of amyotrophic lateral sclerosis/frontotemporal dementia spectrum: a meta-analysis. ( 29349657 )
2018
26
Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. ( 29417336 )
2018
27
Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum. ( 29868980 )
2018
28
Sharing and Empathy in Digital Spaces: Qualitative Study of Online Health Forums for Breast Cancer and Motor Neuron Disease (Amyotrophic Lateral Sclerosis). ( 29903695 )
2018
29
Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis. ( 29169899 )
2018
30
Motor and extra-motor gray matter integrity may underlie neurophysiologic parameters of motor function in amyotrophic lateral sclerosis: a combined voxel-based morphometry and transcranial stimulation study. ( 29417490 )
2018
31
Association between attention-deficit/hyperactivity disorder (ADHD) and amyotrophic lateral sclerosis (ALS). ( 29961556 )
2018
32
ERp57 is protective against mutant SOD1-induced cellular pathology in Amyotrophic Lateral Sclerosis. ( 29409023 )
2018
33
Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression. ( 29409450 )
2018
34
TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. ( 29954341 )
2018
35
Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. ( 29293261 )
2018
36
Amyotrophic Lateral Sclerosis Model. ( 29951816 )
2018
37
Transcriptomics in amyotrophic lateral sclerosis. ( 28930607 )
2018
38
Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. ( 29955173 )
2018
39
Biomarkers of Amyotrophic Lateral Sclerosis: Current Status and Interest of Oxysterols and Phytosterols. ( 29445325 )
2018
40
Cortical Thinning Pattern of Bulbar- and Spinal-onset Amyotrophic Lateral Sclerosis: a Surface-based Morphometry Study. ( 29976279 )
2018
41
Clinical Staging of Amyotrophic Lateral Sclerosis in Chinese Patients. ( 29971035 )
2018
42
Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis. ( 29445154 )
2018
43
Study of occupation and amyotrophic lateral sclerosis in a Danish cohort. ( 29941657 )
2018
44
The Primitive Palmomental Reflex in Amyotrophic Lateral Sclerosis. ( 29566377 )
2018
45
Arginase-1 expressing microglia in close proximity to motor neurons were increased early in disease progression in canine degenerative myelopathy, a model of amyotrophic lateral sclerosis. ( 29408267 )
2018
46
Production of verbs related to body movement in amyotrophic lateral sclerosis (ALS) and Parkinson's Disease (PD). ( 28969902 )
2018
47
Association between attention-deficit/hyperactivity disorder and amyotrophic lateral sclerosis. ( 29958655 )
2018
48
How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? ( 29371752 )
2018
49
Caregiver experience, health-related quality of life and life satisfaction among informal caregivers to patients with amyotrophic lateral sclerosis: a cross-sectional study. ( 29964322 )
2018
50
Unraveling the Complexity of Amyotrophic Lateral Sclerosis Survival Prediction. ( 29962944 )
2018

Variations for Lateral Sclerosis

Expression for Lateral Sclerosis

Search GEO for disease gene expression data for Lateral Sclerosis.

Pathways for Lateral Sclerosis

Pathways related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 DCTN1 NEFH SIGMAR1 SOD1 TARDBP
2
Show member pathways
11.37 DCTN1 NEFH PRPH
3
Show member pathways
10.98 ALS2 NEFH PRPH SOD1

GO Terms for Lateral Sclerosis

Cellular components related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.72 ANG C9orf72 SIGMAR1 SOD1 UBQLN2
2 axon GO:0030424 9.56 ALS2 C9orf72 NEFH SETX
3 myelin sheath GO:0043209 9.54 NEFH SOD1 VCP
4 lipid droplet GO:0005811 9.13 FIG4 SIGMAR1 VCP
5 growth cone GO:0030426 9.02 ALS2 ANG C9orf72 SETX SIGMAR1
6 cytoplasm GO:0005737 10 ALS2 ALS2CR12 C9orf72 DCTN1 FUS HNRNPA1

Biological processes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of autophagosome assembly GO:2000785 9.16 C9orf72 UBQLN2
2 locomotory behavior GO:0007626 9.13 ALS2 FIG4 SOD1
3 neurofilament cytoskeleton organization GO:0060052 8.62 NEFH SOD1

Molecular functions related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dynein complex binding GO:0070840 8.62 DCTN1 NEFH

Sources for Lateral Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....